Cencora Biosimilars Chiefs Talk Adalimumab Pricing, Interchangeability And The IRA
Executives From Former AmerisourceBergen Firm Discuss Latest US Biosimilars Developments
With several Humira biosimilars entering the US market, price competition was fiercer and faster than expected in the second half of 2023, according to Cencora. The former AmerisourceBergen firm’s biosimilars experts Brian Biehn and Connor Nell touch on topics including adalimumab trends, ophthalmology and oncology biosimilars, and the Inflation Reduction Act in a Q&A with Generics Bulletin.
You may also be interested in...
As part of a wide-ranging discussion of its biosimilars business as it reported nine-month results, Sandoz has revealed that it is considering launching its Tysabri (natalizumab) biosimilar Tyruko “at risk” in the US, while also providing an update on its progress with adalimumab as well as certain key pipeline assets.
Amgen’s Amjevita, the first biosimilar of Humira to launch in the US, hasn’t made headway into the US market, according to Samsung Bioepis’ quarterly market report on the US biosimilars market.
Boehringer Ingelheim says it is pushing ahead with an earlier than expected launch of a deep-discounted unbranded version of its Cyltezo adalimumab biosimilar in the US, as it looks to compete with other Humira rivals.